Atherectomy Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Rising Prevalence of Peripheral & Coronary Artery Disease

Peripheral artery disease affects more than 200 million people worldwide, most acutely in aging populations with diabetes and metabolic syndrome. The expanding burden raises procedural complexity because heavily calcified lesions respond poorly to plain balloon angioplasty. Current U.S. and European guidelines now recommend endovascular interventions for infra-inguinal lesions under 25 cm, opening a larger pool of candidates for atherectomy. Hospitals report that older patients present with longer, more complex occlusions that require vessel-preparation techniques to achieve acceptable luminal gain. Consequently, device makers emphasize systems able to debulk eccentric calcium while minimizing embolic events. The long-term demographic tailwind supports double-digit growth in procedure volumes for at least the next decade.

Growing Adoption of Minimally Invasive Endovascular Procedures

Hospitals and outpatient centers prefer shorter stays and quicker ambulation, pushing physicians to select techniques that reduce anesthesia time and wound complications. Medicare reimbursements for OBL interventions reached USD 6.8 billion across 6,308 facilities in 2023. Atherectomy fits this shift because most systems are compatible with 6Fr sheaths, allowing same-day discharge. Ambulatory surgical centers have posted an 8.06% CAGR in atherectomy procedure counts as vascular surgeons and advanced practice providers gain proficiency. Rising comfort among payors with OBL safety metrics further lifts utilization, reinforcing a feedback loop that sustains capital purchases of new systems. Comparable trends in Europe and advanced Asia-Pacific economies are visible albeit at lower absolute volumes.

Favorable Reimbursement Incentives for Office-Based Labs (U.S.)

Historically, CMS set higher relative value units for peripheral atherectomy in OBLs than in hospital outpatient departments, creating a financial tailwind for community-based vascular practices. While the 2024 Physician Fee Schedule reduced payment for over 300 OBL codes, atherectomy still commands sufficient margin for practices operating at moderate volume. Recent code assignments for intravascular lithotripsy, which often complements atherectomy, boosted average payments by USD 8,000, signaling that innovative vessel-preparation modalities can secure premium coverage when backed by robust evidence. The interplay between reimbursement revisions and clinical guidelines will determine whether OBLs maintain their current share of the atherectomy devices market.

Laser Systems with Active Aspiration Lower Distal-Embolization Risk

Second-generation laser catheters integrate aspiration ports proximal to the ablation window, removing particulate debris before it migrates downstream. In a 402-patient registry, the Phoenix system achieved procedural success exceeding 99%, with embolization rates of only 2%. These safety gains are critical as operators tackle longer chronic total occlusions and severely calcified in-stent restenosis that previously required open bypass. Reduced complication risk expands eligibility among frail patients and those with limited runoff vessels, thereby widening the addressable base for laser-enabled atherectomy.

Limited Long-Term Evidence of Superiority vs. PTA/Stenting

The 2,005-patient ECLIPSE trial reported no statistical advantage for orbital atherectomy over plain balloon angioplasty in preventing target vessel failure before drug-eluting stent implantation00450-7/abstract). This neutral outcome echoes prior peripheral registries in which atherectomy reduced amputation risk yet increased repeat intervention rates. Evidence-based payors may therefore restrict reimbursement to subgroups with demonstrated benefit, constraining volume growth in regions that prioritize randomized data over operator preference.

High Device & Capital Costs for Providers

Rotational atherectomy consoles can exceed USD 150,000 and require single-use burrs priced above USD 2,000. OBL operators already face CMS payment that covers barely one-fifth of thrombectomy procedural costs, forcing careful case selection. Capital intensity favors integrated health systems capable of amortizing equipment across multiple sites, potentially squeezing smaller vascular practices out of the atherectomy devices market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Atherectomy Devices Market Segment Analysis

Directional systems generated 41.78% of atherectomy devices market revenue in 2025, reflecting surgeon preference for precise plaque excision and compatibility with post-dilation balloons. The atherectomy devices market size for directional platforms is projected to grow at a steady 7.08% CAGR to 2031 as new cutter-head geometries improve crossing profile without sacrificing debulking capacity. Laser catheters represent the fastest-rising modality at 7.74% CAGR because aspiration-assisted designs significantly lower embolic risk. Rotational and orbital devices remain essential for densely calcified coronary and iliac lesions yet face scrutiny following neutral ECLIPSE outcomes. 

Competitive positioning hinges on differentiated burr coatings, real-time feedback algorithms, and bundled service contracts. Abbott’s Diamondback 360 leverages a diamond-embedded crown that orbits eccentrically to sand down calcium, whereas Boston Scientific’s Jetstream incorporates front-cutting blades plus aspiration for in-stent restenosis. University-industry projects such as milli-scale robotics foreshadow next-generation systems capable of remote navigation through tortuous neurovascular beds. FDA guidance on Predetermined Change Control Plans allows manufacturers to pre-specify software updates, shortening iteration cycles and accelerating innovation cadence.

Peripheral vascular disease interventions captured 57.45% of atherectomy devices market share in 2025 as femoropopliteal and below-the-knee lesions make up the bulk of global endovascular workload. The segment benefits from rising diabetes incidence and wider screening programs that detect occlusive disease earlier. Neurovascular procedures, however, will post the fastest expansion at 7.86% CAGR, propelled by growth in middle meningeal artery embolization for chronic subdural hematomas. Combination therapy strategies that unite clot retrieval, mechanical debulking, and pharmacologic lysis promise to broaden atherectomy’s role in stroke-adjacent care pathways. Coronary artery disease remains a steady but slower-growing application, with adoption tempered by neutral trial data and abundant stent options.

Hospitals and tertiary surgical centers accounted for 63.05% of atherectomy devices market revenue in 2025 thanks to comprehensive imaging and standby surgical backup. Yet ambulatory surgical centers are scaling faster—an 7.93% CAGR—because payors reward same-day discharge and lower facility fees. The atherectomy devices market size tied to ambulatory volumes could surpass USD 668.3 million by 2031 if reimbursement remains favorable. OBLs occupy a middle ground; they thrived on 2018-2023 payment levels but now face margin compression. Quality-focused OBL operators respond by integrating outcomes registries and strict appropriateness criteria to safeguard payer confidence.

Geography Analysis

North America and APAC Atherectomy Devices Market

North America generated 38.74% of atherectomy devices market revenue in 2025 on the back of high procedural density, entrenched reimbursement, and robust clinical research infrastructure. The region’s growth moderates to mid-single-digit rates as volume shifts from hospital inpatient to outpatient venues. The atherectomy devices market size in Asia-Pacific will expand at an 8.08% CAGR through 2031, underpinned by domestic manufacturing incentives and accelerating cardiovascular disease prevalence. China’s Fourteenth Five-Year Plan calls for local production of high-end interventional devices, positioning regional firms to undercut imports without compromising quality. Japan and South Korea, meanwhile, leverage mature reimbursement systems that now recognize vessel-preparation codes, stimulating early adoption.

EMEA and LATAM Atherectomy Devices Market

Europe remains the third-largest regional segment, characterized by evidence-oriented purchasing committees influenced by the Medical Device Regulation. Hospitals emphasize long-term safety registries; therefore, suppliers that document reduced reintervention rates achieve preferred-vendor status. Innovation uptake is fastest in Germany and the Netherlands where OBL equivalents—practice-based cath labs—operate under bundled diagnosis-related group payments. Latin America and Middle East & Africa collectively account for less than 10% of global sales but show high-single-digit growth as private insurers expand coverage for peripheral vascular procedures.

Regulatory Landscape

In the United States, atherectomy systems are regulated as cardiovascular devices through the FDA 510(k) pathway. The Auryon Atherectomy System clearance (K260244), issued on April 10, 2026, points to continued regulatory throughput for system updates and configuration changes. In Europe, MDR (EU) 2017/745 classification and technical documentation requirements apply. In April 2026, the European Commission endorsed updated MDCG 2021-24 Rev. 1 classification guidance and released Version 5 of the Manual on borderline and classification, which can affect intended-use positioning, the scope of clinical evaluation, and recertification planning for legacy platforms.

Value Chain Analysis

The atherectomy value chain includes upstream inputs such as diamond-coated components for rotational and orbital systems, precision cutter assemblies for directional devices, and laser diodes plus optical fibers for laser platforms. Downstream, the flow covers device OEM manufacturing, sterilization and packaging, and distribution through direct hospital and IDN contracting as well as regional distributors that enable capital equipment placement and recurring single-use catheter sales. For laser atherectomy, the supply chain is more vertically integrated and concentrated, with a smaller set of global manufacturers combining laser source design, fiber-optic delivery, and catheter engineering into proprietary console-and-consumable ecosystems that support installed-base lock-in and service-driven revenue.

Market Opportunities and Future Outlook

Ongoing FDA 510(k) activity across atherectomy modalities reflects product-cycle momentum in peripheral and complex lesion workflows, and it creates room for suppliers that can simplify vessel preparation while lowering complication risk and reducing capital pressure on outpatient sites. The current clearance anchors include Eximo Medical’s Auryon Atherectomy System (FDA 510(k) K260244, April 10, 2026), Bard Peripheral Vascular’s Rotarex Atherectomy System (FDA 510(k) K242757, January 30, 2025), and Cardio Flow’s FreedomFlow Orbital Circumferential Atherectomy System configuration (FDA 510(k) K250723, April 25, 2025). Alongside the shift toward 6Fr compatibility and same-day discharge pathways, these clearances support opportunities for vendors that package capital placement, training, and consumable logistics for hospitals, ASCs, and office-based labs.

Clinical practice is converging around combination strategies for severe calcification, with integrated treatment protocols and bundled offerings pairing atherectomy with other plaque-modification technologies. Evidence also highlights where patient selection remains important. The Dual-Prep Registry (2026) reported 7.6% 1-year major adverse cardiovascular events when atherectomy was followed by intravascular lithotripsy in severely calcified coronary lesions, while the 2025 ECLIPSE randomized trial reported neutral differentiation for routine orbital atherectomy versus a balloon-first strategy in eligible lesions. Differentiation is increasingly tied to data-backed indication focus (calcified subsets, bifurcations, complex anatomy), device-plus-therapy pathways (atherectomy plus drug-coated balloons or lithotripsy), and workflow enablers such as cloud-connected consoles that capture procedural parameters for quality reporting in outpatient settings.